Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that the Phase 3 IMforte trial has established a new milestone in the treatment of extensive-stage small cell lung cancer (ES-SCLC).

The study demonstrated that the combination of Zepzelca (lurbinectedin) and atezolizumab as first-line maintenance therapy significantly improved survival outcomes compared to atezolizumab alone.

A biopharmaceutical scientist in their lab, studying a newly-diagnosed therapy-related acute myeloid leukemia. .

Patients receiving the combination saw a 46% reduction in the risk of disease progression or death, with median overall survival reaching 13.2 months versus 10.6 months for those on atezolizumab alone. Median progression-free survival was also notably longer at 5.4 months compared to 2.1 months.

These results, presented at the 2025 ASCO Annual Meeting and published in The Lancet, mark the first time a Phase 3 trial has shown such clinically meaningful benefits in both progression-free and overall survival for ES-SCLC maintenance therapy.

The safety profile was consistent with known effects, with no new safety concerns observed. The findings support Zepzelca plus atezolizumab as a potential new standard of care for patients with ES-SCLC who have completed induction therapy without progression.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical firm committed to creating transformative treatments for serious neurological and cancer conditions. They target areas with significant unmet medical needs, often where limited or no alternatives are available. Their pipeline features both approved therapies and innovative drug candidates at various stages of development.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.